Biotechnology News and Research

RSS

Insilico and SK Biopharmaceuticals partner to develop AI-driven neuroimmune therapies

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system.

22 Jun 2026

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

For a child diagnosed with neuroblastoma-the most common infant cancer, occurring when early nerve cells grow out of control-the path to treatment isn't simple.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

Accelerating drug discovery through AI, automation, and next-generation DMTA

Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.

From TTP plc 19 Jun 2026

Insilico Medicine to showcase AI-driven drug breakthroughs at BIO 2026 International Convention

Insilico Medicine will attend the BIO 2026 International Convention, held from June 22 to 25 at the San Diego Convention Center.

18 Jun 2026

Computer models could design more effective probiotic supplements

Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, new University of Virginia School of Medicine research reveals.

18 Jun 2026

Researchers uncover genetic cause of spontaneous spinal CSF leaks

Researchers at Cedars-Sinai Health Sciences University and Johns Hopkins University have identified genetic mutations that may explain why some people develop a spontaneous cerebrospinal fluid (CSF) leak in the spine.

17 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Synthetic biology platform unmasks hidden bacterial targets of bacteriophages

An interdisciplinary team of Rice University researchers has uncovered previously unknown relationships between bacteriophages - viruses that infect bacteria - and their bacterial hosts, offering a powerful new tool for next-generation microbiome engineering.

17 Jun 2026

UVA neurologist investigates Medicare policy effects on stroke patients

After identifying significant differences in stroke care and outcomes for patients on different Medicare plans, a UVA Health doctor is launching an ambitious effort to better understand the sources of those differences and ensure patients get the best care possible.

16 Jun 2026

UVA joins SPARK GLOBAL initiative to accelerate the development of new medicines

The University of Virginia has joined the SPARK GLOBAL initiative to accelerate the development of new medicines and find solutions for the most urgent and complex healthcare challenges of our time.

15 Jun 2026

Single-dose gene therapy extends healthy lifespan in older mice

A research team from the Universitat Autònoma de Barcelona (UAB) has shown that a one-time administration of a gene therapy expressing the metabolic factor FGF21 can prolong health span in old mice.

15 Jun 2026

Biotechnology breakthrough could revolutionize treatment for neurodegenerative diseases

A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has achieved a significant breakthrough in biotechnology that could revolutionize treatment strategies for neurodegenerative diseases.

12 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026

New hybrid lens design drastically cuts 3D microscopy costs and complexity

A team led by Raju Tomer, professor of biological sciences at Columbia University, has created a new design for microscopes and microscope lenses that could push 3D tissue imaging beyond state-of-the-art systems while drastically cutting costs and complexity.

10 Jun 2026

Critical Path Institute opens registration for 2026 Global Impact Conference

Critical Path Institute (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington Marriott at Metro Center in Washington, D.C.

10 Jun 2026

Laverock Therapeutics reports key oncology research milestones

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced key in-vivo functional milestones across its T-cell and macrophage oncology programs for solid tumor indications.

From Laverock Therapeutics 10 Jun 2026

Study identifies key protein driving colon cancer drug resistance

One of the most widely used chemotherapeutic agents for colorectal cancer is 5-fluorouracil (5-FU), a cornerstone treatment that has improved outcomes for countless patients.

9 Jun 2026

New geroscience initiative aims to accelerate anti‑aging therapies

Albert Einstein College of Medicine has launched the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL), a new initiative designed to help biotechnology and pharmaceutical companies advance therapies that target the biology of aging.

9 Jun 2026

How Programmable Nanobiology Could Drive the Fifth Industrial Revolution

Professor Heddle's insights on nanobiology and AI highlight their potential to innovate drug delivery and vaccine development, addressing critical health needs.

9 Jun 2026